ADVERTISEMENT

Covid-19: Lancet retracts paper that halted hydroxychloroquine trials

Veerman_12

Well-Known Member
Aug 30, 2019
3,054
2,791
113
Retraction made after Guardian investigation found inconsistencies in data
Sarah Boseley Health editor

Thu 4 Jun 2020 15.43 EDTLast modified on Thu 4 Jun 2020 16.27 EDT

Shares
355


The Lancet paper that halted global trials of hydroxychloroquine for Covid-19 because of fears of increased deaths has been retracted after a Guardian investigation found inconsistencies in the data.

The lead author, Prof Mandeep Mehra, from the Brigham and Women’s hospital in Boston, decided to ask the Lancet for the retraction because he could no longer vouch for the data’s accuracy.

The journal’s editor, Richard Horton, said he was appalled by developments. “This is a shocking example of research misconduct in the middle of a global health emergency,” he told the Guardian.

A Guardian investigation had revealed errors in the data which was provided for the research by US company Surgisphere. These were later explained by the company as some patients being wrongly allocated to Australia instead of Asia. But more anomalies were then picked up. A further Guardian investigation found that there were serious questions to be asked about the company itself.

An independent audit company was asked to examine a database provided by Surgisphere to ensure it had the data from more than 96,000 Covid-19 patients in 671 hospitals worldwide, that it was obtained properly and was accurate.

Surgisphere’s CEO, Sapan Desai, had said he would cooperate with the independent audit, but it is understood he refused to give the investigators access to all the data they asked for.

In a statement on Thursday, Mehra said: “Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process.”

The Lancet study had a dramatic impact on attempts to find out whether the antimalarial drug hydroxychloroquine, and its older version, chloroquine, could help treat patients with Covid-19. The US president, Donald Trump was among those who backed the drug before any high-quality trial evidence had been published.

The World Health Organization and several countries suspended randomised controlled trials that were set up to find an answer. Those trials have now been restarted. Many scientists were angry that they had been stopped on the basis of a trial that was observational and not a “gold standard” RCT.

Mehra had commissioned an independent audit of the data after scientists questioned it.

In its investigation, the Guardian put a detailed list of concerns to Desai about the database, the study findings and his background. He responded: “There continues to be a fundamental misunderstanding about what our system is and how it works.

“There are also a number of inaccuracies and unrelated connections that you are trying to make with a clear bias toward attempting to discredit who we are and what we do,” he said. “We do not agree with your premise or the nature of what you have put together, and I am sad to see that what should have been a scientific discussion has been denigrated into this sort of discussion.”
 
@kaskaskiakid nothing? Can't admit you were wrong? That you gloated and ran your mouth for weeks just to be proven wrong?

Cowardly is what that is.

I see you. We all do.
 
  • Like
Reactions: Distancefix
I do find it interesting that they never respond when things like this are brought to light. Cowardly might be a bit strong...I mean in a message board not a fox hole. But you would think the nay sayers wouldn't be so silent.

I get their hate for Trump, I so disliked Obama but I also tried to weed out as much bias as I could when I analyzed his decisions and policy and to be measured to a degree when I talked about him to the other side. Mainly because I didn't want to look ignorant when something the Press etc. spewed and I took up that talking point with fervor only to look like a fool later.

So many who are on the other side these days don't seem to have any issue with regurgitating the propaganda of the left wing media.
 
Sorry for the delay, my life doesn't revolve around Mosports forum.

Have test trials been completed? NO Has CDC approved? NO Are doctors now recommending hydroC as treatment? NO
 
Sorry for the delay, my life doesn't revolve around Mosports forum.

Have test trials been completed? NO Has CDC approved? NO Are doctors now recommending hydroC as treatment? NO

Did trials get discontinued because people with a political agenda publish a hasty article that mainstream media ran with? Yes.
 
Study finds hydroxychloroquine, the drug taken by Trump to ward off COVID-19, doesn't prevent coronavirus infection


The drug President Trump said he was taking to prevent COVID-19 failed another test Wednesday, when a study showed it did not protect against infections.

The new study by University of Minnesota and published in the New England Journal of Medicine, showed hydroxychloroquine wasn't better than a placebo at preventing the development of COVID-19 in someone who was exposed to the coronavirus that causes it.

The 821 participants in the clinical trial were health care workers or first responders, or lived in a household with someone who was. Half the volunteers took five days of hydroxychloroquine, a drug used to treat autoimmune diseases like lupus and rheumatoid arthritis, and the other half received a placebo. Participants and doctors did not know who was getting the active drug.

Apparently your magic bean failed another test. Begin your search for article to support your opinion.
 
Last edited:

My article is literally from yesterday. There is no more recent widespread study, so good try, but swing and a miss.

Also proof Duck doesn't have me on ignore. Why else would he randomly post that right after I discredited his nonsense?
 
Your citation is positive proof. Duck's is fake. Gotcha!!

Mine is far more recent (yesterday), and a cursory Google search will tell you that now actual trials can begin to show whether it's beneficial or not.

Anything saying it DOESN'T work is opinion based on a fake study.

God I hope you weren't in charge of teaching kids to cite sources at Ste Gen...
 
veerman, do you ever get tired of being wrong??? A mind is a terrible thing to waste. I understand how the simpleminded can be fooled by Don the Con. When will you learn your cult loyalty will only make you look more foolish????

Released yesterday. This article specifically explains that database in Lancet report was suspect and the reason for the retraction.

I will be waiting for your apology. You may want a lysol chaser to wash down eating your words.


HEALTH
Study: Hydroxychloroquine had no benefit for hospitalized Covid-19 patients, possibly closing door to use of drug


By MATTHEW HERPER @matthewherper

JUNE 5, 2020

Reprints
AP_20097764418755-645x645.jpg

JOHN LOCHER/AP
Amajor clinical trial showed the malaria drug hydroxychloroquine had no benefit for patients hospitalized with Covid-19, likely closing the door to the use of the highly publicized medicine in the sickest patients — a use for which it was widely prescribed as the pandemic hit the U.S.

The results come from a study called RECOVERY, funded by the U.K. government, that sought to randomly assign large numbers of patients to multiple potential treatments in the country’s National Health Service. The goal was to rapidly get answers as to what worked and what didn’t.

“Today’s preliminary results from the RECOVERY trial are quite clear – hydroxychloroquine does not reduce the risk of death among hospitalized patients with this new disease,” University of Oxford epidemiologist Martin Landray, one of the study’s leaders, said in a statement. “This result should change medical practice worldwide and demonstrates the importance of large, randomized trials to inform decisions about both the efficacy and the safety of treatments.”

Related:
Wholesale drug prices — and net prices — keep falling for most drugs
A total of 1,542 received hydroxychloroquine, and 3,132 received usual care. After 28 days of treatment, 25.7% of those on hydroxychloroquine and 23.5% of those received usual care had died, meaning those on hydroxychloroquine were 11% more likely to die. That difference was not statistically significant.

There was “no beneficial effect” on how long patients stayed in the hospital, or on other outcomes.

The results were shared via a press release, which the study’s lead authors shared on Twitter. They have not been peer-reviewed or published in a medical journal. The researchers said that full results would be shared as soon as possible.

Still, experts said even the top-line results showed they were meaningful.

“This is a hugely important finding that will likely end use of the drug in hospitalized Covid patients, given the other existing data as well,” said Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh. Gellad said that he is curious to see the results of other ongoing studies, and that it is still an open question whether the medicine might work earlier in the disease. “We need real answers there as well,” he said.

Robert Califf, the former Food and Drug Administration commissioner and Alphabet employee, tweeted that the study “essentially rules out benefit of [hydroxychloroquine] in critically ill hospitalized patients.” He wrote that the results showed “no benefit; no major risk.”

Related:
Moderna released scant Covid-19 data to prevent a leak, CEO says
In addition to being used for malaria, hydroxychloroquine is prescribed to treat conditions including rheumatoid arthritis and lupus. But it was known to increase the risk of arrhythmias.

The FDA still authorized emergency use of the drug in hospitalized patients in March, citing the possible safety issues.

Concerns were heightened by a May 22 study in British medical journal the Lancet. That study, which claimed to use a database from hundreds of hospitals around the world, seemed to indicate that treatment with hydroxychloroquine increased the death rate and the rate of arrhythmias.

But on Thursday, the Lancet retracted that study at the request of the authors after widespread questions about the database the study used and the company, Surgisphere, that had provided it. The authors not associated with Surgisphere had asked for the data to be audited, and Surgisphere refused. As such, they wrote, “we can no longer vouch for the veracity of the primary data sources.”

On Wednesday, another group of researchers released results from another randomized study, testing whether giving people hydroxychloroquine shortly after they have been exposed to someone with Covid-19 could prevent disease transmission. That study also showed no benefit, thought some researchers, including Gellad and Califf, say some effect is still possible.

“It could still have an effect given very early in disease, although less and less likely every day that passes,” Gellad said.

There are dozens of studies ongoing with hydroxychloroquine, more than for any other potential Covid-19 treatment, including studies that combine it with antibiotics such as azithromycin or doxycycline. But the results appear to show the benefit of putting resources into testing medicines in large randomized trials, the medical gold standard, during a pandemic.

The RECOVERY trial represented an early and large effort at such studies, testing not only hydroxychloroquine but also a pair of HIV drugs, lopinavir and ritonavir, and the steroid dexamethasone. The study was later expanded to also test using plasma from recovered patients to treat those who are still ill.

About the AuthorReprints
Circular_Matt.png

Matthew Herper
Senior Writer, Medicine

Matthew covers medical innovation — both its promise and its perils.

matthew.herper@statnews.com
@matthewherper
 
Last edited:
veerman, do you ever get tired of being wrong??? A mind is a terrible thing to waste. I understand how the simpleminded can be fooled by Don the Con. When will you learn your cult loyalty will only make you look more foolish????

Released yesterday. This article specifically explains that database in Lancet report was suspect and the reason for the retraction.

I will be waiting for your apology. You may want a lysol chaser to wash down eating your words.


HEALTH
Study: Hydroxychloroquine had no benefit for hospitalized Covid-19 patients, possibly closing door to use of drug


By MATTHEW HERPER @matthewherper

JUNE 5, 2020

Reprints
AP_20097764418755-645x645.jpg

JOHN LOCHER/AP
Amajor clinical trial showed the malaria drug hydroxychloroquine had no benefit for patients hospitalized with Covid-19, likely closing the door to the use of the highly publicized medicine in the sickest patients — a use for which it was widely prescribed as the pandemic hit the U.S.

The results come from a study called RECOVERY, funded by the U.K. government, that sought to randomly assign large numbers of patients to multiple potential treatments in the country’s National Health Service. The goal was to rapidly get answers as to what worked and what didn’t.

“Today’s preliminary results from the RECOVERY trial are quite clear – hydroxychloroquine does not reduce the risk of death among hospitalized patients with this new disease,” University of Oxford epidemiologist Martin Landray, one of the study’s leaders, said in a statement. “This result should change medical practice worldwide and demonstrates the importance of large, randomized trials to inform decisions about both the efficacy and the safety of treatments.”

Related:
Wholesale drug prices — and net prices — keep falling for most drugs
A total of 1,542 received hydroxychloroquine, and 3,132 received usual care. After 28 days of treatment, 25.7% of those on hydroxychloroquine and 23.5% of those received usual care had died, meaning those on hydroxychloroquine were 11% more likely to die. That difference was not statistically significant.

There was “no beneficial effect” on how long patients stayed in the hospital, or on other outcomes.

The results were shared via a press release, which the study’s lead authors shared on Twitter. They have not been peer-reviewed or published in a medical journal. The researchers said that full results would be shared as soon as possible.

Still, experts said even the top-line results showed they were meaningful.

“This is a hugely important finding that will likely end use of the drug in hospitalized Covid patients, given the other existing data as well,” said Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh. Gellad said that he is curious to see the results of other ongoing studies, and that it is still an open question whether the medicine might work earlier in the disease. “We need real answers there as well,” he said.

Robert Califf, the former Food and Drug Administration commissioner and Alphabet employee, tweeted that the study “essentially rules out benefit of [hydroxychloroquine] in critically ill hospitalized patients.” He wrote that the results showed “no benefit; no major risk.”

Related:
Moderna released scant Covid-19 data to prevent a leak, CEO says
In addition to being used for malaria, hydroxychloroquine is prescribed to treat conditions including rheumatoid arthritis and lupus. But it was known to increase the risk of arrhythmias.

The FDA still authorized emergency use of the drug in hospitalized patients in March, citing the possible safety issues.

Concerns were heightened by a May 22 study in British medical journal the Lancet. That study, which claimed to use a database from hundreds of hospitals around the world, seemed to indicate that treatment with hydroxychloroquine increased the death rate and the rate of arrhythmias.

But on Thursday, the Lancet retracted that study at the request of the authors after widespread questions about the database the study used and the company, Surgisphere, that had provided it. The authors not associated with Surgisphere had asked for the data to be audited, and Surgisphere refused. As such, they wrote, “we can no longer vouch for the veracity of the primary data sources.”

On Wednesday, another group of researchers released results from another randomized study, testing whether giving people hydroxychloroquine shortly after they have been exposed to someone with Covid-19 could prevent disease transmission. That study also showed no benefit, thought some researchers, including Gellad and Califf, say some effect is still possible.

“It could still have an effect given very early in disease, although less and less likely every day that passes,” Gellad said.

There are dozens of studies ongoing with hydroxychloroquine, more than for any other potential Covid-19 treatment, including studies that combine it with antibiotics such as azithromycin or doxycycline. But the results appear to show the benefit of putting resources into testing medicines in large randomized trials, the medical gold standard, during a pandemic.

The RECOVERY trial represented an early and large effort at such studies, testing not only hydroxychloroquine but also a pair of HIV drugs, lopinavir and ritonavir, and the steroid dexamethasone. The study was later expanded to also test using plasma from recovered patients to treat those who are still ill.

About the AuthorReprints
Circular_Matt.png

Matthew Herper
Senior Writer, Medicine

Matthew covers medical innovation — both its promise and its perils.

matthew.herper@statnews.com
@matthewherper

You should read the entire article. It says trials are still required multiple times....
 
ADVERTISEMENT

Latest posts

ADVERTISEMENT